Back to Treatments

Treatment

Pembrolizumab (for MSI-H/dMMR)

1
Conditions
50
Trials
5,000
Participants
45%
Average Safety

Condition Evidence

Colon and rectum cancer

50 trials · 5,000 participants

90% effectiveness · 45% safety
Pembrolizumab (for MSI-H/dMMR) | DFDA